Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl≥50 mL/min: A Retrospective Cohort Study
Conclusion: For NVAF patients with CrCl≥50 mL/min in China, low-dose rivaroxaban (10 mg/day) is a viable alternative to standard doses in preventing IS/SE. In nonoverweight patients (BMI<24 kg/m2), it offers comparable efficacy with enhanced safety.
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/cdr/7021330 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849426915625009152 |
|---|---|
| author | Qing Yan Yide Yuan Jiaqi Liang Yuyang Zhao Yuan Li Jiali Fan Jiahong Xue Qiangsun Zheng |
| author_facet | Qing Yan Yide Yuan Jiaqi Liang Yuyang Zhao Yuan Li Jiali Fan Jiahong Xue Qiangsun Zheng |
| author_sort | Qing Yan |
| collection | DOAJ |
| description | Conclusion: For NVAF patients with CrCl≥50 mL/min in China, low-dose rivaroxaban (10 mg/day) is a viable alternative to standard doses in preventing IS/SE. In nonoverweight patients (BMI<24 kg/m2), it offers comparable efficacy with enhanced safety. |
| format | Article |
| id | doaj-art-9eb45b9cd0324a929bd998ed615d00a2 |
| institution | Kabale University |
| issn | 1755-5922 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-9eb45b9cd0324a929bd998ed615d00a22025-08-20T03:29:11ZengWileyCardiovascular Therapeutics1755-59222025-01-01202510.1155/cdr/7021330Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl≥50 mL/min: A Retrospective Cohort StudyQing Yan0Yide Yuan1Jiaqi Liang2Yuyang Zhao3Yuan Li4Jiali Fan5Jiahong Xue6Qiangsun Zheng7Department of Cardiovascular MedicineDepartment of Cardiovascular MedicineDepartment of Cardiovascular MedicineDepartment of Cardiovascular MedicineDepartment of Cardiovascular MedicineDepartment of Cardiovascular MedicineDepartment of Cardiovascular MedicineDepartment of Cardiovascular MedicineConclusion: For NVAF patients with CrCl≥50 mL/min in China, low-dose rivaroxaban (10 mg/day) is a viable alternative to standard doses in preventing IS/SE. In nonoverweight patients (BMI<24 kg/m2), it offers comparable efficacy with enhanced safety.http://dx.doi.org/10.1155/cdr/7021330 |
| spellingShingle | Qing Yan Yide Yuan Jiaqi Liang Yuyang Zhao Yuan Li Jiali Fan Jiahong Xue Qiangsun Zheng Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl≥50 mL/min: A Retrospective Cohort Study Cardiovascular Therapeutics |
| title | Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl≥50 mL/min: A Retrospective Cohort Study |
| title_full | Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl≥50 mL/min: A Retrospective Cohort Study |
| title_fullStr | Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl≥50 mL/min: A Retrospective Cohort Study |
| title_full_unstemmed | Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl≥50 mL/min: A Retrospective Cohort Study |
| title_short | Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl≥50 mL/min: A Retrospective Cohort Study |
| title_sort | outcomes of 10 mg rivaroxaban in nonvalvular atrial fibrillation patients with crcl≥50 ml min a retrospective cohort study |
| url | http://dx.doi.org/10.1155/cdr/7021330 |
| work_keys_str_mv | AT qingyan outcomesof10mgrivaroxabaninnonvalvularatrialfibrillationpatientswithcrcl50mlminaretrospectivecohortstudy AT yideyuan outcomesof10mgrivaroxabaninnonvalvularatrialfibrillationpatientswithcrcl50mlminaretrospectivecohortstudy AT jiaqiliang outcomesof10mgrivaroxabaninnonvalvularatrialfibrillationpatientswithcrcl50mlminaretrospectivecohortstudy AT yuyangzhao outcomesof10mgrivaroxabaninnonvalvularatrialfibrillationpatientswithcrcl50mlminaretrospectivecohortstudy AT yuanli outcomesof10mgrivaroxabaninnonvalvularatrialfibrillationpatientswithcrcl50mlminaretrospectivecohortstudy AT jialifan outcomesof10mgrivaroxabaninnonvalvularatrialfibrillationpatientswithcrcl50mlminaretrospectivecohortstudy AT jiahongxue outcomesof10mgrivaroxabaninnonvalvularatrialfibrillationpatientswithcrcl50mlminaretrospectivecohortstudy AT qiangsunzheng outcomesof10mgrivaroxabaninnonvalvularatrialfibrillationpatientswithcrcl50mlminaretrospectivecohortstudy |